10-Q quarterly report · filed Nov 16, 2026

Larimar Therapeutics, Inc. (LRMR) Q3 2026 10-Q Quarterly Report

Short answer

Larimar Therapeutics, Inc. (LRMR) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$31M
+34.7% YoY · +5.0% QoQ

Source: XBRL data from the Larimar Therapeutics, Inc. (LRMR) Q3 2026 10-Q on SEC EDGAR. USD.

Larimar Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • Net loss $31.1M vs $47.7M YoY, operating loss $32.5M vs $49.5M
  • R&D expenses $25.9M vs $44.9M, G&A $6.5M vs $4.6M
  • Operating cash outflow $119.8M through nine months, cash and securities $128.7M
  • BLA submission completed November 2026, planned launch third quarter 2027 if approved, cash expected through late Q2 2027

Risk Factors

  • BLA filing risk: FDA may refuse filing or deny accelerated approval for nomlabofusp
  • Safety database risk: FDA identified adequacy as a review issue at BLA submission
  • Manufacturing compliance risk: Fill-finish manufacturer received FDA Form 483
  • Launch timing risk: Vendor remediation could delay potential approval or launch
  • Supply-chain risk: Additional fill-finish manufacturer remains under qualification

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Larimar Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.